Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Merck
Dow
Moodys
Boehringer Ingelheim

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,583,174

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,583,174 protect, and when does it expire?

Patent 6,583,174 protects AMITIZA and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: 6,583,174
Title: Composition and method for stabilizing the same
Abstract:Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Habe; Tsuyoshi (Sasayama, JP)
Assignee: Sucampo, A.G. (Zurich, CH)
Application Number:09/688,351
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,583,174
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 6,583,174

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-002 Apr 29, 2008 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sucampo Pharma Llc AMITIZA lubiprostone CAPSULE;ORAL 021908-001 Jan 31, 2006 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Baxter
Express Scripts
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.